Acknowledgments/Disclosures
All procedures performed in this study involving a human participant
adhered to the 1964 Declaration of Helsinki and its later amendments.
Collection of information in this report complied with the Health
Insurance Portability and Accountability Act of 1996.
References
1. O’Keefe GAD, Rao NA. Vogt-Koyanagi-Harada disease. Surv
Ophthalmol . 2017;62(1):1-25. doi:10.1016/j.survophthal.2016.05.002
2. Du L, Kijlstra A, Yang P. Vogt-Koyanagi-Harada disease: Novel
insights into pathophysiology, diagnosis and treatment. Prog Retin
Eye Res . 2016;52(1):84-111. doi:10.1016/j.preteyeres.2016.02.002
3. Patil Y, Garg R, Rajguru J, et al. Vogt–Koyanagi–Harada (VKH)
syndrome: A new perspective for healthcare professionals. J Fam
Med Prim Care . 2020;9(1). doi:10.4103/jfmpc.jfmpc_787_19
4. Sugita S, Takase H, Kawaguchi T, Taguchi C, Mochizuki M.
Cross-reaction between tyrosinase peptides and cytomegalovirus antigen
by T cells from patients with Vogt-Koyanagi-Harada disease. Int
Ophthalmol . 2007;27(2-3):87-95. doi:10.1007/s10792-006-9020-y
5. Read RW, Holland GN, Rao NA, et al. Revised diagnostic criteria for
Vogt-Koyanagi-Harada disease: Report of an international committee on
nomenclature. Am J Ophthalmol . 2001;131(5):647-652.
doi:10.1016/S0002-9394(01)00925-4
6. Rao NA, Sukavatcharin S, Tsai JH. Vogt-Koyanagi-Harada disease
diagnostic criteria. Int Ophthalmol . 2007;27(2-3):195-199.
doi:10.1007/s10792-006-9021-x
7. Depeursinge A, Racoceanu D, Iavindrasana J, et al. Fusing Visual and
Clinical Information for Lung Tissue Classification in HRCT Data.Artif Intell Med . Published online 2010:ARTMED1118. doi:10.1016/j
8. Yang P, Zhong Y, Du L, et al. Development and evaluation of
diagnostic criteria for vogt-koyanagi-harada disease. JAMA
Ophthalmol . 2018;136(9):1025-1031. doi:10.1001/jamaophthalmol.2018.2664
9. Tsai JH, Sukavatcharin S, Rao NA. Utility of lumbar puncture in
diagnosis of Vogt-Koyanagi-Harada disease. Int Ophthalmol .
2007;27(2-3):189-194. doi:10.1007/s10792-007-9044-y
10. Kitaichi N, Matoba H, Ohno S. The positive role of lumbar puncture
in the diagnosis of Vogt-Koyanagi-Harada disease: Lymphocyte subsets in
the aqueous humor and cerebrospinal fluid. Int Ophthalmol .
2007;27(2-3):97-103. doi:10.1007/s10792-006-9016-7
11. Norose K, Yano A, Aosai F, Segawa K. Immunologic analysis of
cerebrospinal fluid lymphocytes in Vogt-Koyanagi-Harada disease.Investig Ophthalmol Vis Sci . 1990;31(7):1210-1216.
12. Damico FM, Kiss S, Young LH. Vogt-Koyanagi-Harada disease.Semin Ophthalmol . 2005;20(3):183-190.
doi:10.1080/08820530500232126
13. Kato Y, Kurimura M, Yahata Y, Tajima K, Kato T.
Vogt-Koyanagi-Harada’s disease presenting polymorphonuclear pleocytosis
in the cerebrospinal fluid at the early active stage. Intern Med .
2006;45(12):779-781. doi:10.2169/internalmedicine.45.1669
14. El Sanharawi M, Sandali O, Naudet F. Ultrasound biomicroscopy of the
ciliary body in ocular/oculodermal melanocytosis. Am J
Ophthalmol . 2013;156(3):627-628. doi:10.1016/j.ajo.2013.05.030
15. Lohman BD, Gustafson CA, McKinney AM, Sarikaya B, Silbert SC. MR
imaging of Vogt-Koyanagi-Harada syndrome with leptomeningeal
enhancement. Am J Neuroradiol . 2011;32(9):169-171.
doi:10.3174/ajnr.A2279
16. Hayasaka Y, Hayasaka S. Almost simultaneous onset of
Vogt-Koyanagi-Harada syndrome in co-workers, friends, and neighbors.Graefe’s Arch Clin Exp Ophthalmol . 2004;242(7):611-613.
doi:10.1007/s00417-004-0888-9
17. Vargas-Ferrer J, Zamora-Mostacero V. Re-Detectable Positive RT-PCR
Test Results in Recovered COVID-19 Patients: The Potential Role of ACE2.Disaster Med Public Health Prep . 2020;14(4):E36-E37.
doi:10.1017/dmp.2020.276
18. Esteve C, Catherine FX, Chavanet P, Blot M, Piroth L. How should a
positive PCR test result for COVID-19 in an asymptomatic individual be
interpreted and managed? Med Mal Infect . 2020;50(8):633-638.
doi:10.1016/j.medmal.2020.09.014
19. Santamaria A, Chang J, Savarain C. SARS-CoV-2 among the Potential
Viral Triggers for Vogt-Konayagi-Harada Disease: First Case Report and
Literature Review. Ocul Immunol Inflamm . 2021;00(00):1-7.
doi:10.1080/09273948.2021.1966052
20. Aggarwal K, Agarwal A, Jaiswal N, et al. Ocular surface
manifestations of coronavirus disease 2019 (COVID-19): A systematic
review and meta-analysis. PLoS One . 2020;15(11 11):1-20.
doi:10.1371/journal.pone.0241661
21. Benito-Pascual B, Gegúndez JA, Díaz-Valle D, et al. Panuveitis and
Optic Neuritis as a Possible Initial Presentation of the Novel
Coronavirus Disease 2019 (COVID-19). Ocul Immunol Inflamm .
2020;28(6):922-925. doi:10.1080/09273948.2020.1792512
22. Nauen DW, Hooper JE, Stewart CM, Solomon IH. Assessing Brain
Capillaries in Coronavirus Disease 2019. JAMA Neurol . 2021;78(6).
doi:10.1001/jamaneurol.2021.0225
23. Yu H, Sun T, Feng J. Complications and Pathophysiology of COVID-19
in the Nervous System. Front Neurol . 2020;11.
doi:10.3389/fneur.2020.573421
24. Koralnik IJ, Tyler KL. COVID-19: A Global Threat to the Nervous
System. Ann Neurol . 2020;88(1). doi:10.1002/ana.25807
25. Koralnik IJ, Tyler KL. COVID-19: a global threat to the nervous
system Running head: Neurologic manifestations of COVID-19. Wiley
Online Libr . 2020;88(1).
26. Eatz T, Al-Khersan H, Tanenbaum R, Sridhar J. Does social media have
a place in ophthalmology practice? Expert Rev Ophthalmol .
2021;16(5). doi:10.1080/17469899.2021.1941877
27. Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19)
Affect the Eyes? A Review of Coronaviruses and Ocular Implications in
Humans and Animals. Ocul Immunol Inflamm . 2020;28(3).
doi:10.1080/09273948.2020.1738501
28. Pascarella G, Strumia A, Piliego C, et al. COVID-19 diagnosis and
management: a comprehensive review. J Intern Med . 2020;288(2).
doi:10.1111/joim.13091
29. Bettach E, Zadok D, Weill Y, Brosh K, Hanhart J. Bilateral anterior
uveitis as a part of a multisystem inflammatory syndrome secondary to
COVID-19 infection. J Med Virol . 2021;93(1).
doi:10.1002/jmv.26229
30. Saraceno JJF, Souza GM, dos Santos Finamor LP, Nascimento HM,
Belfort R. Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1
nCoV-19 (AZD1222) vaccine. Int J Retin Vitr . 2021;7(1).
doi:10.1186/s40942-021-00319-3
31. Papasavvas I, Herbort CP. Reactivation of Vogt-Koyanagi-Harada
disease under control for more than 6 years, following anti-SARS-CoV-2
vaccination. J Ophthalmic Inflamm Infect . 2021;11(1).
doi:10.1186/s12348-021-00251-5